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Abstract
Bone remodeling is controlled by the actions of bone-degrading osteoclasts and bone-forming 
osteoblasts (OBs). Aging and loss of estrogen after menopause affect bone mass and quality. 
Estrogen therapy, including selective estrogen receptor modulators (SERMs), can prevent bone 
loss and increase bone mineral density in post-menopausal women. Although investigations of the 
effects of estrogen on osteoclast activity are well advanced, the mechanism of action of estrogen 
on OBs is still unclear. The proline-rich tyrosine kinase 2 (Pyk2) is important for bone formation 
and female mice lacking Pyk2 (Pyk2-KO) exhibit elevated bone mass, increased bone formation 
rate and reduced osteoclast activity. Therefore, in the current study, we examined the role of 
estrogen signaling on the mechanism of action of Pyk2 in OBs. As expected, Pyk2-KO OBs 
showed significantly higher proliferation, matrix formation, and mineralization than WT OBs. In 
addition we found that Pyk2-KO OBs cultured in the presence of either 17β-estradiol (E2) or 
raloxifene, a SERM used for the treatment of post-menopausal osteoporosis, showed a further 
robust increase in alkaline phosphatase (ALP) activity and mineralization. We examined the 
possible mechanism of action and found that Pyk2-deletion promotes the proteasome-mediated 
degradation of estrogen receptor α (ERα), but not estrogen receptor β (ERβ). As a consequence, 
E2-signaling via ERβ was enhanced in Pyk2-KO OBs. In addition, we found that Pyk2-deletion 
and E2-stimulation had an additive effect on ERK phosphorylation, which is known to stimulate 
cell differentiation and survival. Our findings suggest that in the absence of Pyk2, estrogen exerts 
an osteogenic effect on OBs through altered ERα and ERβ signaling. Thus, targeting Pyk2, in 
combination with estrogen or raloxifene, may be a novel strategy for the prevention and/or 
treatment of bone loss diseases.
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1. Introduction
Bone remodeling involves the coordinated actions of osteoblasts (OB) and osteoclasts, 
which are regulated by hormones, growth factors, transcription factors, and mechanical 
stimuli (Compston, 2001). Excessive resorption and/or decreased bone formation can lead to 
low bone mass diseases such as osteoporosis. The risk of developing osteoporosis increases 
with age and is common in post-menopausal women due to declining levels of the sex 
steroid hormone, estrogen. Evidence suggests that estrogen replacement therapy, including 
selective estrogen receptor modulators (SERMs), can prevent bone loss thus increasing bone 
mineral density in post-menopausal women (Riggs and Hartmann, 2003). Moreover, 
estrogen therapy decreases the risk of skeletal fractures of the hip, spine, and wrist in post-
menopausal women (Compston, 2001). The osteoprotective effects of estrogen are largely 
the result of its pro-apoptotic actions on OCs, which reduces osteoclast numbers and bone 
resorption (Imai et al., 2013, Vinel et al., 2016). Soon after the onset of menopause, 
osteoclast numbers rapidly increase due to the declining levels of estrogen. However, in later 
menopause, reduced OB activity is also observed (Clarke and Khosla, 2010), which 
decreases the bone remodeling rate (Demontiero et al., 2012).
The actions of estrogen on target tissues are mediated by genomic and non-genomic 
pathways through two major estrogen receptor (ER) subtypes, ERα and ERβ (Imai et al., 
2010,Krum and Brown, 2008). The genomic pathway of estrogen occurs through its binding 
to nuclear ERs either by direct interaction of the estrogen-ER complex with estrogen 
response elements (ERE) localized within transcription promoter regions or via indirect 
binding to EREs via other transcription factors. In contrast, the non-genomic actions of 
estrogen or rapid estrogen responses occur via interaction of estrogen with ERs localized at 
the plasma membrane or found in the cytoplasm, resulting in the activation of signal 
transduction pathways, including calcium flux and kinase activation within target cells (Imai 
et al., 2010,Ren and Wu, 2012,Kassem, 1997,Bonnelye and Aubin, 2002,Arts et al., 
1997,Roforth et al., 2014,Tee et al., 2004). A novel estrogen-binding cell surface G-protein-
coupled receptor (GPER1 or GPR30) has also been reported, and is known to mediate the 
non-genomic estrogen pathway by stimulating cyclic AMP (Ren and Wu, 2012,Heino et al., 
2008,Evans et al., 2016,Hadjimarkou and Vasudevan, 2017,Ford et al., 2011).
OBs express both ERα and ERβ, but they are differentially expressed during OB 
differentiation (Bonnelye and Aubin, 2002,Arts et al., 1997). Although some variability in 
the relative expression level of these receptors is seen using different OB cell lines, ERα 
mRNA levels generally appear to increase early in the OB differentiation process and then 
plateau or decrease during mineralization (Arts et al., 1997). In contrast, ERβ mRNA levels 
appear to show a more constitutive expression pattern (Arts et al., 1997,Heino et al., 
2008,Chen et al., 2004,Onoe et al., 1997,Wiren et al., 2002,Teplyuk et al., 2008,Noda-Seino 
et al., 2013,Bord et al., 2003). The ERs are also regulated by estrogen, and one study 
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reported that ERα mRNA is increased after estradiol treatment of human primary OBs for 
24 hours, but no data regarding the effect of estradiol on ERβ mRNA levels was presented 
(Bord et al., 2003). In addition to ERα and ERβ, OBs express GPER1 which has been 
shown to be abundant during the proliferation of mouse and human OBs, although it does 
not appear to be expressed in the MC3T3-E1 osteoblastic cell line (Teplyuk et al., 
2008,Noda-Seino et al., 2013).
The proline-rich tyrosine kinase, Pyk2, belongs to the family of focal adhesion kinases. 
Pyk2 is linked to a variety of cellular activities including proliferation and migration 
(Boutahar et al., 2004,Buckbinder et al., 2007,Gil-Henn et al., 2007,Kacena et al., 2012). 
Pyk2 is important for the regulation of bone mass and for the function of osteoclasts and 
OBs (Buckbinder et al., 2007,Gil-Henn et al., 2007,Kacena et al., 2012,Bruzzaniti et al., 
2005,Eleniste and Bruzzaniti, 2012,Cheng et al., 2013,Eleniste et al., 2016). Our studies and 
others demonstrated that female Pyk2-KO mice exhibit increased bone mass which is due to 
increased OB differentiation and bone formation, as well as decreased osteoclastic bone 
resorption (Buckbinder et al., 2007,Gil-Henn et al., 2007). In the current study, we 
investigated the mechanism of action of Pyk2 and estrogen in OB bone formation in vitro. 
Our studies suggest that the Pyk2-deletion and estrogen-stimulation have an additive effect 
on OB differentiation and mineralization by regulating in part the expression of the ERs in 
OBs.
2. Materials and Methods
2.1. Preparation of calvaria-derived OBs from WT and Pyk2-KO mice
C57BL/6 mice (WT) were obtained from Jackson Laboratories. Pyk2-KO mice (lacking the 
PTK2B gene) were provided by Pfizer, Groton, CT, as described previously (Buckbinder et 
al., 2007,Okigaki et al., 2003). Pyk2-KO mice have been back-crossed for more than 10 
generations and maintained on a C57BL/6 background. All mice used in this project were 
handled according to the guidelines of the American Association for Laboratory Animal 
Science using Institutional Animal Care and Use Committee (IACUC) approved protocols 
(IACUC approval: DS000885R) and in according with the NIH (Guide for the Care and Use 
of Laboratory Animals, 1996).
For the current studies, murine calvarial cells were prepared using the previously described 
protocol (Kacena et al., 2012,Cheng et al., 2013). Mouse calvaria are reliable source of 
primary OBs which are easy to isolate, produce larger quantities of cells than bone-derived 
OBs. In addition, the isolation of OBs from long bones by collagenase digestion also 
releases osteocytes. Both long bone-derived and calvaria-derived OBs have the capacity to 
proliferate, express alkaline phosphatase activity and can underdo differentiation and 
mineralization when cultured in osteogenic media. To prepare OBs, calvaria from neonatal 
mice 2-3 days old were pretreated with 10 mM EDTA in PBS for 30 minutes. For each 
genotype, male and female 2-3 day mouse pups were combined for all preparation of 
calvarial OBs. Next, the calvaria were subjected to sequential collagenase digestions with 
0.1% collagenase type IA (Sigma, MO, USA) from Clostridium histolyticum in serum-free 
α-MEM media (Hyclone, UT, USA) with 1% (v/v) Penicillin/Streptomycin for 30 minutes 
in each digestion at 37°C under shaking conditions (200 rpm). Cells were collected 
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following incubation in collagenase from fractions 3–5, which consist of about 95% OBs or 
OB precursors (Kacena et al., 2012). Calvarial OBs were passaged twice and expanded prior 
to use.
To minimize any potential non-specific estrogenic effects of phenol red or serum, all cells 
were cultured in phenol-red free α-MEM media (Hyclone) supplemented with 2.5% FBS 
(Hyclone). We also compared the effects of E2 on OBs cultured in 2.5% charcoal-stripped, 
heat-inactivated fetal bovine serum (Valley Biomedical, BS3032CS), with similar results, 
and representative data are shown in the supplementary figures. Unless otherwise specified, 
a concentration of 100 nM E2 was used, and was determined in dose-finding studies as 
discussed in the results and supplementary figures. This concentration is consistent with 
relevant literature (Cheng et al., 2002,Taranta et al., 2002,Zhou et al., 2001). To determine if 
E2 was acting through ERα and/or ERβ, selective receptor agonists or antagonists were also 
used. The ERα-specific agonist, propyl-pyrazoletriol (PPT) and the ERβ-specific agonist, 
diarylpropionitrile (DPN) were purchased from Tocris. The ERβ antagonist, 4-[2-
Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) was 
purchased from Sigma and, as reported by the manufacturer, is 36-fold more selective for 
ERβ over ERα. Raloxifene was purchased from Sigma.
2.2. Quantitative Real-time Polymerase Chain Reaction (QPCR)
WT or Pyk2-KO calvarial OBs, 5 × 104 cells, were cultured in 12-well plates in osteogenic 
media (phenol-red free α-MEM (Thermo Fisher, NY, USA) containing 50 μM ascorbic acid 
(AA, Sigma) and 5 mM β-glycerol phosphate (β-GP, Sigma)) in the presence or absence of 
100 nM of 17β-estradiol (E2, Sigma) for 4 or 28 days. Total RNA was isolated using 
RNeasy® Mini Kit (Qiagen, CA, USA). The remnant genomic DNA in RNA samples were 
removed by digestion with DNase I enzyme (Fisher Scientific, PA, USA). Complementary 
DNA (cDNA) was synthesized using the Transcriptor First Strand cDNA Synthesis Kit 
according to the manufacturer's instructions (Roche, IN, USA). QPCR was used to quantify 
mRNA expression from WT and Pyk2-KO OBs. For QPCR, the SYBR® green PCR Master 
Mix (Applied Biosystems, Warringtons, UK) was used following the manufacturer's 
instructions. For each gene, a calibration curve was performed. All oligonucleotide primers 
were tested to ensure correct specificity and sensitivity. All samples were run in the ABI 
Prism® 7000 sequence detection system using STEP1 Software Solutions. The threshold 
cycle (Ct) for each test gene was normalized against the 18S or GAPDH housekeeping 
genes. The housekeeping genes were unaffected by E2 stimulation. For all graphs the ΔCt 
values (absolute mRNA values) are shown which were calculated using the equation ΔCt = 
Ct (gene of interest) – Ct (housekeeping gene). The following oligonucleotide primer 
sequences were used:
ERα forward primer: CTCAACCGCCCGCAGCTCAA
ERα reverse primer: GTAGGCGATGCCCGACTGGC
ERβ forward primer: ACCCTCACTGGCACGTTGCG
ERβ reverse primer: GGCTTGCGGTAGCCAAGGGG
GPER1/GPR30 forward primer: CAGTACGTGATTGCCCTCTTC
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GPER1/GPR30 reverse primer: GTTGCCCACAAAGCCAATAG
c-fos forward primer: ACTTCTTGTTTCCGGC
c-fos reverse primer: AGCTTCAGGGTAGGTG
Collagen type 1 forward primer: AACCTGGTGCGAAAGGTGAA
Collagen type 1 reverse primer: AGGAGCACCAACGTTACCAA
Alkaline phosphatase forward primer: 
ACTGATGTGGAATACGAACTGGATGAGAAGG
Alkaline phosphatase reverse primer: 
CAGTCAGGTTGTTCCGATTCAATTCATACTGC
Osteocalcin forward primer: TCTCTCTGACCTCACAGATGCCAAGC
Osteocalcin reverse primer: GGACTGAGGCTCCAAGGTAGCG
Runx2 forward primer: TCCACAAGGACAGAGTCAGATTACAG
Runx2 forward primer: CAGAAGTCAGAGGTGGCAGTGTCATC
Osterix forward primer: TCTGCTTGAGGAAGAAGCTCACTATGGC
Osterix forward primer: AGGCAGTCAGACGAGCTGTGC
18S forward primer: AGTCCCTGCCCTTTGTACACA
18S reverse primer: CGATCCGAGGGCCTCACTA
GAPDH forward primer: CTTTGGCATTGTGGAAGGGC
GAPDH reverse primer: CAGGGATGATGTTCTGGGCA
2.3. Cell growth and proliferation assays
Cell proliferation was performed using the CellTiter 96® AQeous Non-Radioactive Cell 
Proliferation Assay (MTS) kit according to the manufacturer's instructions (Promega). Cell 
growth was determined by counting the number viable OBs as determined by exclusion of 
0.2% (final concentration) trypan blue. WT or Pyk2-KO calvarial OBs, 5 × 104 cells, were 
cultured in the presence or absence of 100 nM of E2 for 1-4 days in 12-well plates. The 100 
nM E2 concentration used for these studies was based on a dose-finding pilot study (shown 
herein) as well as relevant literature (Cheng et al., 2002,Taranta et al., 2002,Zhou et al., 
2001). 100 nM E2 also produced the highest osteogenic response in primary OBs and in the 
pre-OB cell line, MC3T3-E1 (data not shown). OBs from each group were harvested, and 
the cell number per well was counted using a hemocytometer. For cell viability/cytotoxicity 
assessment, the Cell counting Kit-8 (Dojindo Molecular Technologies) was used as per the 
manufacturer's instructions.
2.4. Quantitative alkaline phosphatase (ALP) activity assay
WT or Pyk2-KO calvarial OBs were cultured in 12-well plates at 5 × 104 cells in osteogenic 
media containing 50 μM AA and 5 mM β-GP in the presence or absence of 100 nM of E2 or 
0.1-10 nM of raloxifene (Sigma) for 4-28 days. Cells were lysed in the mRIPA buffer (50 
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mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% Sodium deoxycholate) supplemented 
with 10 μg/mL leupeptin hydrochloride, 10 μg/mL aprotinin, 10 μg/mL pepstatin, 1 mM 
PMSF, 1mM sodium fluoride, and 1mM sodium orthovanadate. The lysate was sonicated for 
5 minutes, and then centrifuged at maximum speed for 5 minutes and the supernatant was 
collected. ALP activity was assayed by adding cell lysate to ALP substrate containing 2 
mg/mL p-nitrophenyl phosphate (Sigma) in 1.5 M alkaline buffer (Sigma), and then the 
mixture was incubated for 50 minutes at 37°C in a dark atmosphere. The enzymatic reaction 
was stopped by adding 20 mM NaOH to the mixture, and the absorbance at 405 nm was 
recorded using a spectrophotometer. ALP activity was normalized by total protein using a 
Pierce™ BCA protein assay kit.
2.5. Quantitative analysis of mineralization
WT or Pyk2-KO calvarial OBs, 5 × 104 cells, were cultured in 12-well plates in osteogenic 
media containing 50 μM AA and 5 mM β-GP in the presence of E2 (1, 10, 100 nM) or 
raloxifene (0.1-10 nM) for up to 28 days in 2.5 % FBS or 2.5% charcoal stripped FBS 
(supplementary Figure S1). Cells were washed with PBS and fixed in 4% formaldehyde/PBS 
for 15 min and washed twice in PBS and stored at 4°C. Prior to staining, cells were washed 
twice with deionized water (dH2O). Alizarin Red S (40 mM, pH 4.2, Sigma) was used to 
stain calcium deposits in each well for 10 minutes with agitation. The Alizarin Red S stained 
samples were washed 5 times with dH2O, followed by 15 minutes of PBS washing on the 
shaker. Next, the bound Alizarin Red S was extracted with 1% cetyl pyridinium chloride 
(Sigma) in 10 mM sodium phosphate (pH 7.0) for 15 minutes on the shaker at room 
temperature. Calcium deposition was measured by recording the absorption of extracted 
Alizarin Red S at 562 nm using a spectrophotometer.
2.6. Western blot analysis and co-immunoprecipitation studies
WT or Pyk2-KO calvarial OBs, 2 × 105 cells, were cultured in 6-well plates for 4 days in the 
presence or absence of 100 nM of E2. In addition, OBs were differentiated in osteogenic 
media containing 50 μM AA and 5 mM β-GP with or without 100 nM E2 for 28 days. OB 
cells were lysed in mRIPA buffer supplemented with protease/kinase inhibitors as previously 
described. The amount of protein was quantified using the Pierce™ BCA protein assay kit, 
and proteins were then resolved by SDS-PAGE electrophoresis. For co-immunoprecipitation 
studies, 5 μg primary antibody per 500 μg of cell lysate was used. Tubes were incubated at 
4°C overnight with rotation. Immunoprecipitations were performed using protein G-agarose 
beads (Roche) for 1 hr. Immunoprecipitation of ERa was performed using a monoclonal 
antibody (Santa Cruz) followed by Western blotting for ubiquitin with a polyclonal antibody 
(Proteintech) or vice versa. Nitrocellulose membranes were incubated with the primary 
antibody overnight at 4°C. An anti-mouse antibody conjugated with horseradish peroxidase 
(HRP) or anti-rabbit HRP (Promega, WI, USA) were used as secondary antibodies. Proteins 
were detected using the enhanced chemiluminescence (ECL) reagent (SuperSignal™ West 
Pico Chemiluminescence Substrate, Sigma) according to the manufacturer's 
recommendations. Radiographic film was used to record the emitted signal from the 
membrane. As necessary, protein bands were quantified by densitometry using ImageJ 
software.
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2.7. Statistical analyses
All data was reproduced a minimum of twice. All data were analyzed by one-way analysis 
of variance (ANOVA) and/or two-way ANOVA followed by post hoc multiple comparisons 
where appropriate. Data was analyzed by using SPSS 24 software (IBM Corporation, 
Armonk, NY, USA). With the exception of Western blot data, all data are shown as mean ± 
standard error of mean (SEM) of triplicate samples and a significant difference was 
determined at p ≤ 0.05.
3. Results
3.1. Pyk2-KO OBs exhibit higher basal proliferation than WT OBs
To determine if estrogen affects OB proliferation and cell growth, an equal number of 
calvarial-derived OBs from WT and Pyk2-KO mice were cultured in phenol-free growth 
medium supplemented with or without 100 nM 17β-estradiol (E2) for 4 days. The E2 
concentration used was based on a dose-finding pilot study (Figure 3B and supplementary 
Figure S1) as well as relevant literature (Cheng et al., 2002,Taranta et al., 2002,Zhou et al., 
2001). As shown in Figure 1A, Pyk2-KO OB control cultures (without estrogen) had higher 
OB number compared to WT OBs (p<0.05), suggesting that Pyk2-KO OBs maintain a 
higher level of basal proliferation than WT OBs. In cultures treated with E2 for 4 days, WT 
OB number was significantly increased, compared to untreated WT OBs. In contrast, E2 had 
no effect on the number of Pyk2-KO OBs after 1 or 4 days of culture (p<0.05).
Transcription factors of the AP1 complex such as c-fos are highly expressed during OB 
proliferation and in the initial stages of differentiation (Machwate et al., 1995,Wagner, 
2002). Therefore, we examined the effects of E2 on c-fos mRNA levels in WT and Pyk2-KO 
OBs by QPCR (Figure 1B). These studies revealed significantly higher c-fos mRNA levels 
in vehicle-treated Pyk2-KO OBs, compared to WT OBs (2.5 fold, p=0.01), consistent with 
our findings that Pyk2-KO exhibit a higher basal proliferation rate. However, E2 stimulation 
of either Pyk2-KO or WT OBs did not alter c-fos mRNA expression. This latter finding 
differed from the E2-stimulated increase in WT OB number (Figure 1A) and may indicate 
that the upregulation of c-fos mRNA is a transient event.
3.2 Estrogen increases alkaline phosphatase (ALP) activity and mineralization in Pyk2-KO 
OBs
To investigate the effect of E2 on the expression of osteoblast markers during OB 
differentiation, primary calvarial OBs from WT and Pyk2-KO mice were cultured under 
osteogenic conditions in the presence or absence of E2 for either 4 days (early OB markers) 
or 28 days (mature OBs markers). QPCR analysis of collagen type 1, osterix and Runx2 
(early OB differentiation) and osteocalcin (late OB differentiation) was performed. Pyk2-KO 
OBs exhibited significantly higher collagen type 1 mRNA expression than WTs (1.9 fold, 
p=0.03) (Figure 2A). Notably, E2 supplementation also significantly increased collagen type 
1 mRNA expression in Pyk2-KO (p=0.04), but not WT OBs. Runx2 expression was also 
higher in Pyk2-KO OBs but E2 decreased Runx2 expression in Pyk2-KO OBs down to WT 
levels (Figure 2C). These findings are consistent with reports that Runx2 protein is 
upregulated in immature osteoblasts, but downregulated in mature osteoblasts (Komori, 
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2010). However, Osterix, which is expressed early in differentiation was not different 
between WT and Pyk2-KO and was also unchanged in the presence of E2 (Figure 2C). In 
Pyk2-KO OBs cultured for 28 days, we found increased expression of osteocalcin (OCN) 
mRNA compared to WT (8.75 fold, p=0.007). However, no further change in OCN mRNA 
levels were detected in the E2-stimulated Pyk2-KO or WT OBs (Figure 2D).
Using a quantitative biochemical ALP assay, we further examined the effects of E2 on the 
differentiation of OBs lacking Pyk2. WT and Pyk2-KO OBs were grown in osteogenic 
media supplemented without or with E2 for 14 or 28 days. No differences in ALP activity 
were observed between WT and Pyk2-KO OBs cultured with E2 for 14 days (Figure 3A). 
Similar results were obtained when cells were cultured for only 4 days (data not shown). 
However, in 28 day cultures, an increase in ALP activity was observed in Pyk2-KO OBs 
cultured without E2 (13.8±1.7 nM/mL/μg) compared to WT OBs (6.8±0.7 nM/mL/μg) 
(p<0.05). Moreover, E2 supplementation robustly increased ALP activity in Pyk2-KO OBs 
(2-fold, p=0.005) but had no effect on ALP activity in WT OBs. These results suggest that 
Pyk2-deletion promotes ALP catalytic activity, and that long-term culture with E2 (28 days) 
has an additive effect on ALP activity in OBs lacking Pyk2.
Since collagen type 1 expression and ALP activity are key steps involved in OB mineralizing 
activity (Burr and Allen, 2013,Datta et al., 2008,Soares et al., 2008), we examined if E2 
promotes extracellular calcium deposition by Pyk2-KO OBs. For these studies, cells were 
cultured in osteogenic media supplemented with 100 nM E2. In addition, to determine if the 
E2 effects were dose-dependent, we also used 1 nM and 10 nM E2. In WT OBs, a small 
increase in mineralization was observed only in cells supplemented with 100 nM E2. In 
contrast, mineral deposition by Pyk2-KO OBs was markedly increased with both 10 nM and 
100 nM E2, compared to vehicle. In addition, all Pyk2-KO OB treatment groups showed 
significantly higher mineralization than comparable WT OB groups (#) (p<0.05) (Figure 
3B). Similar to our findings with ALP, E2 had an additive effect on calcium deposition by 
Pyk2-KO OBs.
3.3. Raloxifene increases ALP activity and mineral deposition in Pyk2-KO OBs
Raloxifene is an FDA-approved SERM for the treatment of post-menopausal osteoporosis 
(Russell, 2015,Hegde et al., 2016). Raloxifene binds ERα with approximately 3.5-fold 
higher affinity than ERβ, whereas estrogen has a similar binding affinity for both ERα and 
ERβ (Zhu et al., 2006). We investigated if raloxifene also affects the activity of WT and 
Pyk2-KO OBs, similar to17β-estradiol. Cells were cultured in osteogenic media plus 
increasing concentrations of raloxifene as indicated. After 28 days, we performed 
quantitative ALP activity and calcium deposition assays. Raloxifene had no effect on ALP 
activity in WT OBs at any of the concentrations tested, similar to our findings with E2 
(Figure 3C). However, 1 nM and 10 nM raloxifene stimulated ALP activity in Pyk2-KO OBs 
approximately 1.7 fold and 1.4 fold, respectively, compared to the vehicle-treated Pyk2-KO 
OBs (p<0.05) (Figure 4A). At the higher 10 nM concentration, a decrease in mineralization 
was observed compared to 1 nM, which may indicate that the lower concentration of 
raloxifene, as used by others (Taranta et al., 2002) is better tolerated by the Pyk2-KO OBs 
during the long 28 day culture conditions.
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Unlike E2 which increased the mineralization of Pyk2-KO OBs but not WT OBs (Figure 3), 
1 nM and 10 nM raloxifene increased mineral deposition by both Pyk2-KO and WT OBs 
(Figure 4B). Nevertheless, Pyk2-KO OBs still exhibited an overall greater percentage 
increase in calcium deposition in the presence of 0.1, 1 and 10 nM raloxifene than 
comparably-treated WT OBs (e.g. 116% Pyk2-KO vs 44% WT at 1 nM). Together, these 
data reveal that E2 and raloxifene both exert significant osteogenic effects in Pyk2-KO OBs.
3.4. Pyk2-deletion promotes ERα protein degradation
To begin to determine the mechanism of action of Pyk2 in the E2-signaling cascade, we 
examined if Pyk2 regulates the expression of the estrogen receptors. We first examined if 
deletion of Pyk2 and/or E2 stimulation affects the mRNA expression of ERα and ERβ 
(Figure 5). However, QPCR analysis revealed no change in the mRNA expression of either 
ERα or ERβ in WT or Pyk2-KO OBs. E2 can also signal through the membrane estrogen 
receptor, GPER1 (also known as GPR30), which can activate ERa (Heino et al., 
2008,Carmeci et al., 1997,Kang et al., 2015). Our QPCR analyses showed a higher level of 
GPER1 mRNA in Pyk2-KO OBs compared to WT OBs (Figure 5C). In addition, E2 
increased GPER1 mRNA only in Pyk2-KO. Whether the increase in GPER1 mRNA affects 
protein expression and the biological activity of OBs requires further investigation.
Next, we examined possible changes in ERα and ERβ protein levels by Western blotting. 
Calvarial OBs were grown under osteogenic conditions for 4 days (early OBs) or 28 days 
(mature mineralizing OBs) in the presence or absence of E2. Western blot analysis revealed 
lower ERα protein levels in Pyk2-KO OBs compared to WT OBs in day 4 and day 28 
cultures (Figure 5D, 5E and supplementary Figure S2). E2 stimulation did not appear to alter 
ERα protein levels in Pyk2-KO OBs, although a small increase was observed in WT treated 
with E2 for 28 days. With regards to ERβ, in 4 day cultures without E2, Pyk2-KO OBs and 
WT OBs exhibited similar levels of ERβ protein, while in the presence of E2, a small 
increase in ERβ was observed in Pyk2-KO OBs (Figure 5D). In 28 day cultures without E2, 
ERβ protein levels in Pyk2-KO were similar to WT OBs and although E2 had no effect on 
this receptor in Pyk2-KO OBs, an increase in ERβ was observed in WT OBs treated with E2 
(Figure 5D and 5F).
Given that ERα was reduced in Pyk2-KO OBs cultured without E2 for 4 and 28 days, and 
that E2 did not appear to significantly alter ERα protein levels, we examined the possible 
ERα degradation mechanism. Several published studies have shown that ERα can undergo 
proteosome-mediated degradation (Levi-Montalcini et al., 1996,Petrel and Brueggemeier, 
2003). Therefore, we examined the effect of the widely used ubiquitin-proteosome inhibitor, 
MG-132, on ERα protein levels (Park et al., 2009,Kretzer et al., 2010). Given that E2 did 
not have a major effect on ERα protein levels, for these studies, we cultured Pyk2-KO and 
WT OBs without E2, for 4 days and then added 20 μM MG-132 for the final 3 hours of 
culture. Prior to these studies, we confirmed that WT or Pyk2-KO cell viability in the 
presence 5 μM, 10 μM or 20 μM MG-132 were not statistically different to the controls, 
demonstrating it was not cytotoxic to our cells (supplementary Figure S3). After MG-132 
treatment of Pyk2-KO and WT OBs, cells were then lysed and separated by centrifugation 
into the soluble fraction (contains cytosolic proteins) and the insoluble pellet fraction 
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(contains proteins associated with the plasma membrane, nucleus and cytoskeleton) (Figure 
6A). Western blot analysis revealed two major molecular weight forms of ERα, 
corresponding to approximately 66 and 54 kDa, with the lower MW form appearing mostly 
in the pellet fraction of WT OBs. In vehicle-treated WT OBs, total ERα was higher in the 
pellet fraction than the soluble fraction. However, for Pyk2-KO OBs, total ERα was similar 
in both fractions. Although MG-132 treatment did not affect ERα in soluble fraction of WT 
OBs, a decrease in ERα was observed the pellet fractions. In Pyk2-KO OBs treated with 
MG-132, a significant increase in ERα in the soluble fraction was observed as expected, 
while ERα decreased in the pellet. Although the mechanism is still unknown, this finding 
may indicate that MG-132 leads to the redistribution of ERα from the pellet to the soluble 
fraction. Alternatively, MG-132 potentially prevents the degradation of accessory proteins 
which may be important in ERα degradation as reported by others (Ismail and Nawaz, 
2005,Nawaz et al., 1999).
To further explore if ERα was being degraded via the ubiquitin proteosome pathway, we 
treated OBs with MG-132 as described above and then examined its association with 
ubiquitin (Ub) by co-immunoprecipitation followed by Western blot analysis using anti-
ubiquitin (Proteintech) or anti-ERα antibodies (Figure 6B and 6C), and vice versa. MG-132 
increased the levels of the ERα-Ub complex in a dose-dependent manner in Pyk2-KO OBs 
(Figure 6B). For WT OBs, a small increase was only observed in cells treated with 20 μM 
MG-132. Overall, the level of ERα-Ub complex was much higher in Pyk2-KO OBs than 
WTs at all MG-132 concentrations and in the vehicle control group, indicating a basal 
increase in ubiquitin binding to ERα in Pyk2-KO OBs. Multiple molecular weight species 
were also observed, with the most abundant being approximately 24 kDa. A protein species 
corresponding to the ubiquitin monomer (∼8 kDa) was also observed in darker blots. 
Similarly, when the ubiquitin antibody was used for immunoprecipitation, a higher level of 
the Ub-ERα complex was observed in vehicle-treated and MG132-treated Pyk2-KO OBs 
compared to WTs (Figure 6C). These findings suggest that MG-132 prevents the 
degradation of ERα via the ubiquitin proteasome pathway. However, given that Ub-ERα 
complex was higher in vehicle-treated Pyk2-KO OBs, other mechanisms for ERα 
degradation may also be involved.
3.5. ERβ signaling in Pyk2-KO OBs promotes mineralization
Based on our finding that ERα was decreased in Pyk2-KO OBs, we determined if signaling 
via ERβ was the predominate mechanism for the increased mineralizing activity of Pyk2-
KO OB in the presence of E2. First, to determine if ERα signaling was indeed blunted in 
Pyk2-KO OBs, we cultured cells for 21 days under osteogenic conditions, and in the 
presence or absence of the ERα-specific agonist, propyl-pyrazoletriol (PPT). As expected, 
PPT (40 and 100 nM) had no significant effect on the mineralizing activity of Pyk2-KO OBs 
(Figure 7A). WT OBs also failed to show a PPT response. This result was not unexpected 
given that E2 had only a minor effect on WT OBs mineralization when used at 100 nM with 
no effect observed at 1 and 10 nM (Figure 3B). Next, we examined mineral deposition by 
WT and Pyk2-KO calvarial OBs cultured in the presence or absence of the ERβ-specific 
agonist, diarylpropionitrile (DPN). The treatment time and drug concentrations used (100 
nM and 400 nM) were based on our previous experiments and relevant literature (Somjen et 
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al., 2011,Galea et al., 2013). Although WT OBs treated with DPN showed no change in 
mineralization, we observed an increase in mineralization in Pyk2-KO OBs cultured with 
400 nM DPN, compared to vehicle-treated Pyk2-KO OBs (Figure 7B). Lastly, WT and 
Pyk2-KO OBs were cultured in the presence and absence of E2 in combination with 
increasing concentrations of the ERβ-specific antagonist, 4-[2-Phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP). As reported by the 
manufacturer, PHTPP is a synthetic, highly selective antagonist of ERβ and possesses 36-
fold selectivity for ERβ over ERα. As shown in Figure 7C, PHTPP (20, 50 and 100 nM) had 
no effect on WT OBs in the absence of E2, but when added in combination with E2, 
decreased the mineralizing activity of WT OBs. Importantly, PHTPP significantly reduced 
mineralization in Pyk2-KO OBs in the absence of E2, and had an even greater effect on 
Pyk2-KO OBs mineralization when combined with E2. Taken together, these data suggest 
that the ERβ receptor remains functional in Pyk2-KO OBs, and that E2 likely acts via ERβ 
to increase mineral deposition by Pyk2-KO cells.
3.6. Pyk2-deletion and E2-stimulation activate the ERK pathway
OB proliferation and differentiation are controlled by several signaling pathways, including 
mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPKs/ERKs) and 
protein kinase B (AKT). The ERK1 (44 kDa) and ERK2 (42 kDa) proteins are expressed in 
OBs and have important functions in bone metabolism (Ge et al., 2012,Lai et al., 2001). In 
addition, E2 binding promotes the rapid interaction of ERα and ERβ with the c-Src kinase, 
leading to ERK and AKT activation (Marino et al., 2006). Since Pyk2-KO OBs displayed 
significant increases in matrix maturation and mineralization, both of which were further 
increased with E2 or raloxifene, we investigated if Pyk2-deletion and/or E2 affected 
downstream activation of ERK. As shown in Figure 8, Pyk2-KO OBs exhibited higher levels 
of phosphorylated ERK compared to WT OBs. E2 further increased phosphorylated ERK 
(pERK) levels in both Pyk2-KO and WT OBs. In contrast, total ERK was similar between 
WT and Pyk2-KO OBs, and E2 increased total ERK only in Pyk2-KO OBs. The overall 
ratio of pERK/ERK was also higher in Pyk2-KO and was increased with E2 in Pyk2-KO as 
well as WT OBs (Figure 8 graphs). We also investigated if Pyk2-deletion and/or E2 
stimulation affected ERK signaling in OBs cultured for 21 days (mature OBs) (data not 
shown). Our results revealed no differences in phosphorylated ERK or total ERK protein 
levels between WT and Pyk2-KO OBs, with or without E2 stimulation, suggesting that the 
increased mineralization of E2-treated Pyk2-KO OBs was associated with increased ERK 
signaling in early OBs (day 4). Since the activation of AKT is also associated with cell 
growth, proliferation and survival (Burr and Allen, 2013,Ge et al., 2012,Lai et al., 
2001,Mandal et al., 2016,Ayala-Pena et al., 2013), we also examined phosphorylated and 
total AKT in our cells (supplementary Figure S5). However, no differences in 
phosphorylated AKT or total AKT levels between WT and Pyk2-KO OBs cultured for 4 
days, with or without E2 treatment were observed. Taken together, these results suggest that 
Pyk2-deletion combined with E2-stimulation increases the mitogenic activity of early OBs 
through increased ERK phosphorylation and signaling.
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4. Discussion
Bone formation by OBs is essential for bone remodeling as well as fracture repair. Our 
studies and others have shown that Pyk2-KO mice have higher bone mass compared to WT 
mice. OBs from these mice also show increased bone formation activity (Buckbinder et al., 
2007,Gil-Henn et al., 2007). In the current study, we focused on the role of Pyk2 and 
estrogen on OB activity. We determined that Pyk2-KO OBs exhibit higher proliferation and 
differentiation than WT OBs as determined by increases in cell number, c-fos mRNA 
expression, ALP activity and mineralization. Although E2 supplementation for 4 days 
significantly increased the number of WT OBs, it had little effect on Pyk2-KO OBs number. 
However, Pyk2-KO OBs cultured with E2 still exhibited a higher cell number than E2-
treated WT OBs, suggesting a basal increase in Pyk2-KO OB proliferation in our culture 
conditions. Of note, we previously reported that the proliferation of both WT and Pyk2-KO 
OBs is increased by megakaryocytes, which also promoted OB mineralization and increased 
bone mass (Cheng et al., 2013). However, in those studies, the basal proliferation rate 
between Pyk2-KO and WT OBs was similar. These differences are likely due to the different 
culture conditions; in our previous studies we used phenol-red containing media which is 
known to exert weak estrogenic effects (Berthois et al., 1986), whereas in the current studies 
we used phenol-free media as well as reduced serum levels.
During the early stages of differentiation as observed in 4 day cultures, we found that 
collagen type 1 mRNA expression in Pyk2-KO OBs was higher than in WT OBs. Runx2 
was also higher in Pyk2-KO OBs, although osterix was unchanged. At later stages of the OB 
differentiation process (day 21-28), Pyk2-KO OBs also exhibited higher OCN mRNA 
expression, which is a marker of mature OBs. In addition, ALP activity and calcium 
deposition in Pyk2-KO OBs were elevated compared to WT OBs. These results confirm that 
Pyk2 is a negative regulator of OB activity, which is consistent with our previous data as 
well as other published studies (Buckbinder et al., 2007,Kacena et al., 2012,Cheng et al., 
2013,Eleniste et al., 2016). Further, our current data suggest that E2 enhances Pyk2-KO OB 
differentiation to a greater extent than WT OBs. In support of this, E2 enhanced collagen 
type 1 in mature differentiated Pyk2-KO OBs (but not in WT OBs), which is necessary for 
OB mineralization. In addition, Runx2 levels were decreased by E2, which is consistent with 
reports that Runx2 levels are downregulated in mature osteoblasts (Komori, 2010). Our 
studies also demonstrated that E2 has an additive effect on ALP activity and calcium matrix 
deposition in Pyk2-KO OBs. These results were reproduced in media containing hormone-
replete FBS or charcoal-stripped FBS, and using several E2 concentrations. Collectively, our 
data demonstrate that Pyk2-deficiency in OBs leads to accelerated differentiation compared 
to WT OBs, and that this process is further enhanced by E2.
In the current study, we investigated the mechanism of action of Pyk2 in the E2-signaling 
cascades by QPCR and Western blotting. Although ERα and ERα mRNA were similar, we 
found higher GPER1 mRNA in Pyk2-KO which was further increased by E2. GPER1 is a 
membrane estrogen receptor that binds E2 with high affinity. GPER1 also activates kinase 
cascades and calcium flux, and has been shown to phosphorylate ERα, suggesting crosstalk 
between these receptors (Heino et al., 2008,Carmeci et al., 1997,Kang et al., 2015). 
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Although additional studies are required, it is possible that the effects of E2 on increasing 
mineralization in Pyk2-KO may be mediated in part through GPER1/GPR30.
Our finding that ERα protein levels were reduced in Pyk2-KO OBs, compared to WT OBs 
(Figure 5), prompted us to investigate the possible mechanism of degradation through the 
ubiquitin-proteosome degradation pathway. Consistent with published studies reports 
showing proteosome-mediated degradation (Petrel and Brueggemeier, 2003,Chai et al., 
2015,Zhou and Slingerland, 2014), MG-132 increased ERα protein levels in Pyk2-KO OBs, 
and led to the accumulation of ERα in the cytosol (soluble fraction). Moreover, co-
immunoprecipitation assays revealed a concentration-dependent increase in ERa-Ub protein 
complexes in Pyk2-KO OBs treated with MG-132. Although several publication indicate 
that ERβ can also undergo ubiquitin proteasome degradation in some cell types (Sanchez et 
al., 2013,Tateishi et al., 2006), we found similar levels of ERβ in Pyk2-KO OBs and WT 
OBs, suggesting only ERα is degraded in Pyk2-KO OBs. These findings support the idea 
that in the absence of Pyk2, ERα is more rapidly degraded in part via the ubiquitin-
proteosome pathway. However, given that the ERα-Ub protein complexes were higher in 
Pyk2-KO OBs than in WT OBs, even in the absence of MG-132, other mechanisms 
regulating ERα protein complexes may also be involved. It is also known that ERα mRNA 
expression can vary temporally in OBs, and is higher during matrix maturation and then 
decreases during mineralization (Onoe et al., 1997,Wiren et al., 2002,Bord et al., 2003). In 
contrast, ERβ mRNA levels remain relatively constant throughout OB differentiation (Onoe 
et al., 1997,Wiren et al., 2002,Bord et al., 2003). Therefore, the reduced levels of ERα 
observed in Pyk2-KO OBs may reflect an increase in the differentiation phase of Pyk2-KO 
OBs compared to WT OBs. This is also supported by higher ALP and mineralizing activities 
observed in Pyk2-KO OBs.
Published reports largely attribute the anti-resorptive effects of estrogen-depletion on bone 
mass in vivo through its effects on reducing osteoclast number and activity (Imai et al., 
2013,Vinel et al., 2016). However, it has been shown that E2 can stimulate the osteogenic 
differentiation of bone marrow cells derived from ERα-KO mice, as demonstrated by 
increases in collagen type 1 synthesis, ALP activity, and mineralization. Interestingly, 
similar to our findings in E2-treated Pyk2-KO OBs, in published reports, E2-treated ERα-
KO OBs also showed an additive effect of E2 on ALP activity compared to control or E2-
treated WT OBs (Parikka et al., 2005). In another study, it was reported that E2 significantly 
enhanced ALP activity and collagen type 1 mRNA expression in MG-63 osteosarcoma cells 
that had reduced levels of ERα, but not ERβ (Cao et al., 2003,McCauley et al., 2003). On 
the contrary, it was reported that the differentiation of OBs from ERαf/f; Prx-Cre and 
ERαf/f; Osx-Cre mice is significantly decreased when compared to controls (Almeida et al., 
2013). This latter observation may result from a decrease in the ability of mesenchymal stem 
cells to differentiate into OB-lineage cells. Taken together, our findings suggest that the 
enhanced effect of E2 on ALP and mineralization in Pyk2-KO OBs, compared to WT OBs, 
may be mechanistically linked with the decrease in ERα in Pyk2-KO OBs. However, our 
studies also suggest that E2 signaling via ERβ contributes to the increased mineralization of 
Pyk2-KO OBs. Indeed, we found that DPN, an ERβ agonist, increased Pyk2-KO OBs 
mineralization, suggesting that ERβ is active in these cells. Importantly, the ERβ antagonist, 
PHTPP significantly reduced mineralization in Pyk2-KO OBs in the absence of E2, and had 
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an even greater effect on Pyk2-KO OBs mineralization when combined with E2, confirming 
the critical role of ERβ in Pyk2-KO OBs. It is also possible that the increased osteogenic 
effect of E2 on Pyk2-KO OBs proceeds via a mechanism that does not require direct binding 
of E2 to either ERα or ERβ. Although more studies are needed, we found increased 
expression of GPER1 (GPR30) mRNA in Pyk2-KO OBs and with E2 stimulation, which is 
known to phosphorylate and active ERα, providing an alternative route by which 
mineralization might be increased in Pyk2-KO OBs. As another example, E2 signaling also 
occurs through the N-terminal truncated ERα isoform, or the orphan nuclear ER-related 
receptor α (ERRα) which is differentially expressed relative to ERα and ERβ in OBs and 
was reported to affect bone formation (Bonnelye and Aubin, 2002,Parikka et al., 
2005,Bonnelye et al., 2001). In addition, a recent study found that Pyk2 promoted the 
expression and phosphorylation of the androgen receptor (Hsiao et al., 2016), suggesting a 
possible altered signaling of the androgen receptor in Pyk2-KO OBs.
The mechanism of action of raloxifene on target tissue is reported to occur through genomic 
and non-genomic pathways, involving both ERα and ERβ (Tee et al., 2004,Jordan et al., 
2001). It has been shown that raloxifene preferentially binds ERα with approximately 3.5 
fold higher affinity than ERβ (Zhu et al., 2006). Raloxifene exerts its estrogenic effects on 
bone by decreasing the remodeling rate, reducing osteoclast activity, and maintaining OB 
activity (Hegde et al., 2016). In addition to its anti-resorptive activity, several studies suggest 
that raloxifene may act as an osteogenic agent by increasing cell proliferation as well as 
Runx2 mRNA and collagen type 1 mRNA expression in primary human OBs. These effects 
were found to be partly mediated via ERK1 and ERK2 activation (Noda-Seino et al., 
2013,Taranta et al., 2002). With respect to raloxifene in our studies, we found that raloxifene 
robustly enhances both ALP activity and mineral deposition in Pyk2-KO OBs, while 
exerting only a modest positive effect on the mineralizing activity of WT OB. Furthermore, 
the decreased levels of ERα but not ERβ in Pyk2-KO OBs, may suggest that the osteogenic 
effects of raloxifene may occur through ERβ, similar to our proposed mechanism for the 
actions of E2 in Pyk2-deficient OBs.
To examine if Pyk2-deletion affects signaling cascades that are common to ERα and/or 
ERβ, we examined the activity of the mitogenic protein, ERK, and the anti-apoptotic 
protein, AKT. Although AKT levels were similar in WT and Pyk2-KO OBs, Pyk2-KO OBs 
exhibited enhanced ERK phosphorylation compared to WT OBs (Figure 12). It is well-
established that MAPKs are activated by phosphorylation of tyrosine/threonine residues 
though ERK, leading to the activation of nuclear transcription factors such as c-fos and c-jun 
during early OB differentiation (Marie, 2008). Consistent with this, ERK activation 
increases ALP activity (Jaiswal et al., 2000), OCN mRNA levels and mineralization during 
OB differentiation (Ge et al., 2007,Matsushita et al., 2009). Conversely, in mice that lack 
ERK1/ERK2, bone mineralization is substantially reduced when compared to WT mice 
(Matsushita et al., 2009). Published evidence suggests that E2 stimulation of MC3T3-E1 
osteoblastic cells enhances ERK phosphorylation via ERα and prevents OB apoptosis (Yang 
et al., 2013). In our study, we also found that E2-stimulation further increases ERK 
phosphorylation in Pyk2-KO OBs. Given the osteogenic effects of Pyk2-deletion on OB 
proliferation and differentiation, we speculate that Pyk2-deletion leads to an increase in 
ERK phosphorylation which consequently increases OB differentiation markers, ALP 
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activity and mineralizing activity. In addition Pyk2-deletion may affect other signaling 
pathways, such as p38 which is member of the MAPKs family of proteins, similar to ERK. 
It is also known that p38 promotes cell proliferation (Zhang and Liu, 2002) and plays an 
important role in the differentiation of calvarial OBs, bone marrow cells, and some OB cell 
lines (Wang et al., 2007,Rodriguez-Carballo et al., 2016,Hu et al., 2003), although this 
remains to be confirmed in our studies.
In summary, our results indicate that in normal OBs, Pyk2 acts a negative regulator of 
proliferation, differentiation and mineralization. Furthermore, Pyk2 appears to be an integral 
component of the E2-ERα/ERβ signaling cascade which regulates ERK signaling and 
consequently, OB proliferation and mineralizing activity. In addition, Pyk2 may stabilize 
ERα protein levels by preventing proteosome-mediated degradation of ERα. Thus, in the 
absence of Pyk2, ERα protein levels are decreased via ubiquitin-proteosome mediated 
degradation, which increases ERK signaling and OB activity. In the presence of E2, ERK 
signaling is further increased, most likely through ERβ, which promotes OB differentiation 
and mineralization (Figure 9). In conclusion, our studies suggest that Pyk2-deletion or 
chemical inhibitors of Pyk2 will promote bone formation and potentiate the effects of 
estrogen (or raloxifene) on OB matrix formation and mineralization. Given that Pyk2-
deficient osteoclasts exhibit decreased osteoclast activity, and that estrogen and SERMs (e.g. 
raloxifene) are potent anti-resorptive agents, our studies also suggest that Pyk2-targeted 
inhibitors, in combination with anti-resorptive therapies, may have dual actions that prevent 
bone loss and increase skeletal mass in vivo.
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Highlights
• Pyk2 deletion increases osteoblast differentiation and mineralization
• Pyk2 deletion promotes ERα degradation via the ubiquitin proteosome 
pathway
• Inhibition of ERβ signaling inhibits the effects of estrogen on Pyk2-KO OBs
• Estrogen increases ERK signaling as well as osteoblast differentiation and 
mineralization in Pyk2-deficient osteoblasts
• Pyk2 targeted therapies in combination with estrogen receptor agonists may 
increase bone mass
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Figure 1. Effect of Pyk2-deletion and estrogen on OB cell number and proliferation
A) WT and Pyk2-KO OBs from neonatal calvaria were plated at 5×104 cells and cultured in 
the presence or absence of 100 nM E2. Cells were counted after 4 days. B) QPCR analysis 
was used to determine c-fos mRNA expression in WT and Pyk2-KO OBs cultured for 4 days 
in the presence or absence of 100 nM E2. 18S was used as the housekeeping control to 
normalize the mRNA transcript under investigation. The 18S Ct values were WT (14.26 
± 0.09) and Pyk2-KO (14.56 ± 0.21). The data are shown as mean of ΔCT ± SEM of 
triplicate or quadruplicate samples. Statistical significance of p<0.05 is indicated (*) for 
effects within a genotype and (#) for significant changes for the same treatment between WT 
and Pyk2-KO OBs.
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Figure 2. Effect of Pyk2-deletion and estrogen stimulation on markers of OB activity
WT and Pyk2-KO OBs were cultured under osteogenic conditions containing ascorbic acid 
and β-glycerol phosphate (β-GP) in the presence or absence of 100 nM E2 for 4 days or 28 
days. QPCR analysis was used to determine mRNA expression of collagen type 1, osterix 
and Runx2 (day 4) or osteocalcin (OCN; day 28). Data are absolute mRNA using 18S (A; 
D) or GAPDH (B; C) as the calibrator gene. The mean Ct values for the relevant 
housekeeping genes are: collagen (WT, 14.26 ± 0.09; Pyk2-KO, 14.56 ± 0.21); osterix (WT, 
21.33 ± 0.09; Pyk2-KO, 21.65 ± 0.05); Runx2 (WT, 21.13 ± 0.07; Pyk2-KO, 20.92 ± 0.07) 
and OCN (WT, 14.26 ± 0.09; Pyk2-KO, 14.56 ± 0.21). The graphs shown as mean of ΔCT ± 
SEM of triplicate samples. Statistical significance of p<0.05 is indicated (*) within a 
genotype and (#) between genotypes. White and black bars represent no E2 or plus E2, 
respectively.
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Figure 3. Effect of Pyk2-deletion and estrogen stimulation on OB activity
A) WT and Pyk2-KO OBs were cultured under osteogenic conditions containing ascorbic 
acid and β-GP, with or without 100 nM E2. ALP activity was quantified at day 14 and 28. B) 
WT and Pyk2-KO OBs were cultured in osteogenic media without E2 or with 1, 10 or 100 
nM E2 for 28 days, and then analyzed using a quantitative mineralization assay which is 
based on elution of Alizarin Red S from calcium bound to the collagen matrix. All assays 
were performed in triplicate and error bars represent mean ± SEM. Experiments were 
repeated 3 or more times. Statistical significance of p<0.05 is indicated (*) within a 
genotype and (#) between genotypes for the matching E2-treated groups.
Posritong et al. Page 24
Mol Cell Endocrinol. Author manuscript; available in PMC 2019 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. The effect of raloxifene on ALP activity and mineralization in WT and Pyk2-KO OBs
WT and Pyk2-KO OBs were cultured under osteogenic conditions with or without 0.1, 1.0 
and 10 nM raloxifene for 28 days. The treatment duration was based on the most robust E2 
effects, while the raloxifene concentrations were determined based on pilot studies and 
published literature (Lin et al., 2004,Matsumori et al., 2009). Assays were performed in 
triplicate and repeated 3 or more times. The error bars are mean ± SEM. A) ALP activity 
and B) Calcium deposition. Statistical significance of p<0.05 is indicated (*) for treatments 
within a genotype and (#) indicates significance between genotypes for the same raloxifene 
concentration.
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Figure 5. Expression of ERs in WT and Pyk2-KO OBs
A-C) WT and Pyk2-KO OBs were cultured with or without 100 nM E2 for 4 days. The 
mRNA expression levels for ERα, ERβ and GPER1 (GPR30) were determined by QPCR. 
GAPDH was used as the housekeeping gene. The mean Ct values for the GAPDH 
housekeeping gene are: ERα and ERβ (WT, 14.0 ± 0.04; Pyk2-KO, 14.01 ± 0.04), and 
GPER1 (WT, 21.13 ± 0.07; Pyk2-KO, 20.89 ± 0.06). The data are mean ± SEM of 
quadruplicate samples. Statistical significance of p<0.05 is indicated as (*) for E2 treatment 
effects within a genotype. The (#) indicated significance between genotypes cells for the 
same treatment. D-F) WT and Pyk2-KO OBs were cultured for 4 days (D) or 28 days (E and 
F) with or without 100 nM E2. Total cell lysates from WT and Pyk2-KO OBs were resolved 
by SDS-PAGE and blotted using antibodies specific to ERα or ERβ as indicated (also see 
supplementary Figure S2). ERα and ERβ protein levels were quantified by densitometry 
using ImageJ software and normalized to β-actin levels.
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Figure 6. Effect of MG-132 on the subcellular distribution of ERα
A) WT and Pyk2-KO calvarial OBs were cultured for 4 days. The proteasome inhibitor, 
MG-132 (20 μM), was added for the final 3 hours of culture. Cells were lysed with mRIPA 
buffer and then separated into the soluble and insoluble pellet fractions by centrifugation at 
13,000 rpm. Western blotting and densitometry was performed to determine the ratio of 
ERα/β-actin. According to the manufacturer's specification sheets, the ERα antibody 
(sc-787) can detect multiple isoforms with the molecular weight of native ERα being 66-67 
kDa. Short isoforms of 54, 48 and 36 kDa were also reported. Experiments were performed 
twice and representative data are shown. B) WT and Pyk2-KO OBs were cultured as above 
and then treated for the final 3 hours with different concentrations of MG-132 (0, 5, 10, 20 
μM) as indicated. Cell lysates were subject to immunoprecipitation with a monoclonal 
antibody to ERα, followed by Western blotting using a polyclonal antibody to ubiquitin. (*) 
indicates a darker blot showing the ∼8 kDa ubiquitin band. Membranes were stripped and 
reblotted for ERα. The ratio of the densitometry of the IP:ERα/B:Ub blot (upper panel) to 
the IP:ERα/B:ERα blot (lower panel) was used to normalize for the amount of the 
immunoprecipitated protein (ratio graph). Please see supplementary Figure S4 for full blots. 
C) WT and Pyk2-KO OBs were cultured with and without E2 and then treated for 3 hours 
with 20 μM MG-132 for the final 3 hours. Ubiquitin was immunoprecipitated and blotted for 
ERα. The membrane was stripped and then reblotted for ubiquitin. The ratio of the 
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densitometry of the IP:Ub/B:ERα blot (upper panel) to the IP:Ub/B:Ub blot (lower panel) 
was used to normalize for the amount of the immunoprecipitated protein (ratio graph). All 
major ubiquitin or ERα bands observed in blots were used for the densitometry analyses.
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Figure 7. The effects of an ERβ agonist and antagonist on OB mineralization
WT and Pyk2-KO OBs were cultured for 21 days under osteogenic conditions containing, 
A) the ERβ-specific agonist (DPN) or B) the ERα-specific agonist (PPT). C) Cells were 
cultured with the ERβ-specific antagonist (PHTPP) with or without E2 for 28 days. After 
culture, the cells were stopped and analyzed for mineral deposition using a quantitative 
Alizarin Red S mineralization assay. Experiments were performed in triplicate and 
replicated 2-3 times and representative data are shown. For A) and B), statistical significance 
of p<0.05 is indicated as (*) for drug effects within a genotype or (#) between genotypes. C) 
In the PHTPP graphs, the (#) indicates significance between WT (no E2) versus Pyk2-KO 
(no E2), whereas (&) indicates significant differences between WT (+E2) versus Pyk2-KO 
(+E2) for the same drug concentration. The symbols (^) and (€) are used to indicate WT (no 
E2) versus WT (+E2), and Pyk2-KO (no E2) versus Pyk2-KO (+E2), respectively.
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Figure 8. The effect of Pyk2-deletion and estrogen on ERK phosphorylation in OBs
WT and Pyk2-KO OBs were cultured for 4 days with or without 100 nM E2. Cell lysates 
were blotted with antibodies to phosphorylated ERK (pERK) or total ERK as indicated. 
Phosphorylated-ERK runs as a doublet at 42 kDa and 44 kDa. An additional non-specific 
band approximating the molecular weight of phosphorylated p38 was also observed with the 
pERK antibody (arrowhead). Actin is used as the loading control. Protein bands were 
analyzed by densitometry (both p42 and p44 were used) and the ratio for effect differences is 
shown. The graphs for the ratio of pERK/actin, total ERK/actin and pERK/ERK are as 
indicated. Graphs showing the relative effects of E2 on either pERK or ERK are also shown. 
N=3 replicates.
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Figure 9. Schematic representation of the proposed actions of Pyk2 and estrogen on OBs
We postulate that inhibition of Pyk2 activity increases ERα degradation via the ubiquitin-
proteosome pathway, which leads to an increase in ERK signaling and OB proliferation, and 
consequently promotes OB differentiation and mineralization activity. E2-stimulation, most 
likely acting through ERβ, has an additive effect on ERK signaling, which further promotes 
OB activity, leading to an increase in bone formation.
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